$OSCR

Oscar Health (OSCR) reported Q2 2026 revenue of $4.9B, up 70% year over year, and net income of $362M. Effectuated membership rose to 2.96M, and medical loss ratio improved to 79.2%. Management reiterated full-year revenue guidance of $18.7B to $19.0B and raised earnings from operations guidance to $500M to $700M, citing disciplined pricing and favorable prior-period reserves, while noting potential higher churn from CMS eligibility verification.

GoodRx reported Q2 revenue of $200.4M, down 1%, and raised its full-year outlook, citing a projected 70% revenue increase from Pharma Direct. Oscar Health reported first-half 2026 results with revenue up 70% to $4.9B and record profitability, attributing gains to its AI platform and “Oswal” tools. Both cited shifting consumer insurance needs.

Oscar Health, Inc. reported record first-half profitability with $1 billion net income and improved medical loss ratio, citing disciplined pricing and favorable utilization. The company raised 2026 earnings from operations guidance to $500 million to $700 million, with full-year MLR expected at 81.5% to 82.5% and SG&A ratio 15.6% to 16.1%. It highlighted AI tools and CMS program integrity reviews.

Oscar Health (NYSE:OSCR) reported Q2 CY2026 revenue of $4.88 billion, up 70.4% year over year, beating Wall Street estimates by 2.9%, according to the company. GAAP EPS was $1.10, up from -$0.89 a year earlier, above consensus. The stock rose 11.8% to $34.10. Analysts expect next-12-month revenue growth of 25.5%.

Oscar Health reported a $361.8 million Q2 profit and $1.04 billion net income for the first six months of 2026, with revenue up 70% year over year to $4.9 billion. Membership rose to 2.9 million. Oscar said its medical loss ratio fell to 79.2% from 91.1% and raised its 2026 outlook, citing cost control and prior-period reserve development.

Oscar Health, Inc. (OSCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 oscarhealthsecondquarter20.htm EX-99.1 Document Oscar Health, Inc. ir.hioscar.com News Release Oscar Health Announces Record Financial Results for First Half 2026 and Raises Full Year 2026 Outlook New York, NY, August 6, 2026 – Oscar Health, Inc. (“Oscar” or the “Compan

Barchart highlights Oscar Health (OSCR), saying shares have risen about 106% over 52 weeks and recently hit an all-time high of $33.10. The article cites a 100% “Buy” technical opinion, Weighted Alpha of +139.87, and a Trend Seeker buy signal. Market cap is $9.21B, with revenue and earnings growth projections and analyst price targets from $13 to $35.

A Florida man, Larry Gruber, said Oscar Health of Florida did not count Amgen’s Enbrel copay coupon toward his deductible/out-of-pocket maximum, forcing him to pay until he met cost-sharing. The article cites Avalere Health and The AIDS Institute on copay accumulator prevalence and discusses insurer and drugmaker arguments, plus state regulation.

Schlosser Mario sold 47,500 indirectly-held shares of Oscar Health, Inc. (OSCR) at an average of $31.24 ($29.50–$31.65, $1.48M total) across 3 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Oscar Health (OSCR) shares rose after an SEC Form 4 showed CEO and director Mark T. Bertolini sold 1.24M Class A shares worth about $35.7M, according to the filing. The stock was reported to have gained as much as ~12.23% during Wednesday’s trading.